Johnson & Johnson (NYSE:JNJ) Holdings Lessened by Walter & Keenan Wealth Management LLC IN ADV

Posted by on Apr 19th, 2023

Walter & Keenan Wealth Management LLC IN ADV decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 14.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,212 shares of the company’s stock after selling 8,085 shares during the quarter. Johnson & Johnson accounts for about 3.2% of Walter & Keenan Wealth Management LLC IN ADV’s investment portfolio, making the stock its 5th largest position. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Johnson & Johnson were worth $8,163,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. State Street Corp lifted its holdings in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after purchasing an additional 310,473 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $161.01 on Wednesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69. The company’s 50 day moving average is $157.50 and its 200 day moving average is $167.03. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The company has a market cap of $419.32 billion, a PE ratio of 23.89, a price-to-earnings-growth ratio of 2.86 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $2.67 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Atlantic Securities boosted their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. UBS Group began coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, Guggenheim began coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.